| Name | Title | Contact Details |
|---|
Columbus Mckinnon is a New York-based company that manufactures and distributes material handling products including hoists and cranes for sectors such as food and utilities.
Established in 1946 as well as being family owned and operated since 1946, the Fletcher Jones Company has grown into one of the largest and most respected automotive groups in the world. Our Preferred Owner Benefits include many amenities such as a complimentary Mercedes-Benz courtesy vehicle and a complimentary hand car wash.
Toda la regulación del sector energético colombiano compilada y actulizada en una sola plataforma
High to Low Voltage has made a name for itself sourcing electrical solutions for projects of all sizes, from smaller companies to large-scale data centers with enormous energy demands. Our expert sales team knows how to find the perfect equipment regardless of your electrical needs. High to Low Voltage. A business born out of a love of electrical equipment and necessity! Weve been problem-solving urgent electrical equipment needs for over 20 years, eager to put that experience to work for you in the moments that you need it most.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.